MX2019008115A - Formulaciones topicas de detomidina. - Google Patents

Formulaciones topicas de detomidina.

Info

Publication number
MX2019008115A
MX2019008115A MX2019008115A MX2019008115A MX2019008115A MX 2019008115 A MX2019008115 A MX 2019008115A MX 2019008115 A MX2019008115 A MX 2019008115A MX 2019008115 A MX2019008115 A MX 2019008115A MX 2019008115 A MX2019008115 A MX 2019008115A
Authority
MX
Mexico
Prior art keywords
topical
detomidine
subject
formulations
formulation
Prior art date
Application number
MX2019008115A
Other languages
English (en)
Inventor
Tsipori Omer
Zamansky Mark
Original Assignee
Clexio Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clexio Biosciences Ltd filed Critical Clexio Biosciences Ltd
Publication of MX2019008115A publication Critical patent/MX2019008115A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente formulaciones tópicas que comprenden aproximadamente 0.001 a aproximadamente 3 % en peso de detomidina o una sal de la misma; y, un portador que es adecuado para administración tópica a la piel de un sujeto, en donde el portador opcionalmente comprende un solubilizante miscible en agua que está presente en una cantidad de hasta 40% en peso de la formulación; en donde la formulación tiene un pH de 4.5 a 9, y, en donde la formulación proporciona tratamiento prolongado, sustancialmente no sistemático para el dolor. También se proporcionan métodos para proporcionar tratamiento prolongado, no sistémico para el dolor en un sujeto en necesidad de esto, que comprenden administrar tópicamente al sujeto las formulaciones tópicas actualmente descritas.
MX2019008115A 2017-01-06 2018-01-05 Formulaciones topicas de detomidina. MX2019008115A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762443174P 2017-01-06 2017-01-06
PCT/US2018/012579 WO2018129313A1 (en) 2017-01-06 2018-01-05 Topical detomidine formulations

Publications (1)

Publication Number Publication Date
MX2019008115A true MX2019008115A (es) 2019-10-24

Family

ID=61054537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008115A MX2019008115A (es) 2017-01-06 2018-01-05 Formulaciones topicas de detomidina.

Country Status (14)

Country Link
US (2) US20190343805A1 (es)
EP (1) EP3565526B1 (es)
JP (1) JP2020505322A (es)
KR (1) KR20190110561A (es)
CN (1) CN110114059A (es)
AU (1) AU2018205217B2 (es)
BR (1) BR112019011961A2 (es)
CA (1) CA3049389A1 (es)
DK (1) DK3565526T3 (es)
ES (1) ES2982022T3 (es)
IL (1) IL266448B2 (es)
MX (1) MX2019008115A (es)
PL (1) PL3565526T3 (es)
WO (1) WO2018129313A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3820448A2 (en) * 2018-07-11 2021-05-19 Clexio Biosciences Ltd. Topical detomidine formulations
US20210323929A1 (en) * 2018-07-18 2021-10-21 Clexio Biosciences Ltd. Purified Detomidine, Process of Preparing and Methods of Use
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
US11185532B2 (en) * 2019-05-01 2021-11-30 Clexio Biosciences Ltd. Methods of treating pruritus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10256774A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Transmucosale und transdermale Arzneimittel mit verbesserter Wirkstoffresorption
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
WO2011127586A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Topical treatments for pain
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
EP2803668A1 (en) * 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
EP3033427A4 (en) * 2013-08-14 2017-05-31 The Board Of Trustees Of The University Of the Leland Stanford Junior University Compositions and methods for controlling pain
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain

Also Published As

Publication number Publication date
US20190343805A1 (en) 2019-11-14
PL3565526T3 (pl) 2024-09-09
EP3565526A1 (en) 2019-11-13
BR112019011961A2 (pt) 2019-11-05
IL266448B2 (en) 2023-11-01
AU2018205217A1 (en) 2019-05-23
CA3049389A1 (en) 2018-07-12
KR20190110561A (ko) 2019-09-30
ES2982022T3 (es) 2024-10-14
DK3565526T3 (en) 2024-05-13
WO2018129313A1 (en) 2018-07-12
JP2020505322A (ja) 2020-02-20
CN110114059A (zh) 2019-08-09
EP3565526B1 (en) 2024-04-17
IL266448B1 (en) 2023-07-01
AU2018205217B2 (en) 2023-11-09
IL266448A (en) 2019-06-30
US20230172909A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
MX2019008115A (es) Formulaciones topicas de detomidina.
MX2020012595A (es) Composiciones farmaceuticas topicas.
MX361590B (es) Suministro topico de composiciones para la piel que tienen ph bajo.
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
PH12017500136A1 (en) Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
MX2022001736A (es) Formulaciones y tratamientos topicos.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
PH12018500910A1 (en) Novel method of use and compositions
PH12020552142A1 (en) Composition for muscle relaxation
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
WO2020012415A3 (en) Topical detomidine formulations
MX2018011539A (es) Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas.
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
MX2020007062A (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
SG11201909144VA (en) Bacterial secretome for use in the treatment of skin lesions
WO2014091146A3 (fr) Utilisation cosmetique d'un extrait de germe de caroube en tant qu'agent actif amincissant
MX2018013477A (es) Acidos carboxilicos para tratar/prevenir una enfermedad de la piel.
ZA202006986B (en) Dantrolene formulations and methods of their use
CA3168207A1 (en) Cellular uptake